Fennec Pharmaceuticals (TSX:FRX) Total Assets : C$64.04 Mil (As of Dec. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals Total Assets?

Fennec Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2024 was C$64.04 Mil.

During the past 12 months, Fennec Pharmaceuticals's average Total Assets Growth Rate was 43.00% per year. During the past 3 years, the average Total Assets Growth Rate was 149.40% per year. During the past 5 years, the average Total Assets Growth Rate was 117.10% per year. During the past 10 years, the average Total Assets Growth Rate was 87.10% per year.

During the past 13 years, Fennec Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 243.30%. The lowest was -67.30%. And the median was 27.85%.

Total Assets is connected with ROA %. Fennec Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2024 was -15.73%. Total Assets is also linked to Revenue through Asset Turnover. Fennec Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2024 was 0.16.

Fennec Pharmaceuticals Total Assets Historical Data

The historical data trend for Fennec Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Total Assets Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

40.24

28.69

36.60

36.04

64.04

Fennec Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Assets	Get a 7-Day Free Trial															36.04	93.66	86.56	79.81	64.04

Fennec Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Fennec Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	-8.366	+	72.4
	=	64.03

Fennec Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2024 )	+	Total Liabilities (Q: Dec. 2024 )
	=	-8.366	+	72.4
	=	64.03

Fennec Pharmaceuticals (TSX:FRX) Total Assets Explanation

Total Assets is connected with ROA %.

Fennec Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %	=	Net Income (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	-11.312	/	( (79.814	+	64.035)	/ 2 )
	=	-11.312	/	71.9245
	=	-15.73 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Fennec Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2024 is

	Asset Turnover
=	Revenue (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
=	11.291	/	( (79.814	+	64.035)	/ 2 )
=	11.291	/	71.9245
=	0.16

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Fennec Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

FENC:USA RV41:Germany

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Executives

Rostislav Christov Raykov	Director, Senior Officer
Chris Anigeron Rallis	Director
Robert Christopher Andrade	Senior Officer
Adrian J. Haigh	Senior Officer
Khalid Islam	Director